Lipancrea

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lipancrea

Understanding Lipancrea

Lipancrea is a pharmaceutical preparation containing a mixture of digestive enzymes known as pancreatin. These enzymes are naturally produced by the pancreas and are essential for the breakdown and absorption of nutrients from food.

Composition and Function

The primary components of Lipancrea are enzymes derived from porcine pancreatic glands. These include:

  • Lipase: Responsible for breaking down dietary fats (lipids) into fatty acids and glycerol.
  • Amylase: Facilitates the digestion of carbohydrates (starches) into simple sugars.
  • Protease: Aids in the breakdown of proteins into peptides and amino acids.

By supplementing these enzymes, Lipancrea assists the body in processing macronutrients when the pancreas is unable to produce or release sufficient amounts of its own digestive secretions.

Mechanism of Action

Lipancrea is typically formulated as gastro-resistant granules or capsules. This design ensures that the enzymes are protected from the acidic environment of the stomach. The enzymes are released only when they reach the small intestine, where the environment is more alkaline. Once released, they act locally in the duodenum to catalyze the hydrolysis of fats, proteins, and starches, mimicking the natural digestive process. This allows for more effective nutrient absorption and helps manage symptoms associated with impaired digestion.

Regulatory References

  1. Pancrelipase: MedlinePlus Drug Information
  2. MedlinePlus Drug Information

What side effects are possible with Lipancrea?

Possible Side Effects and Safety Information

Lipancrea (Pancreatin) is classified by regulatory authorities based on the nature and frequency of reported adverse reactions. The safety profile primarily reflects effects on the gastrointestinal system, consistent with its function as a digestive enzyme.

Frequency-Classified Adverse Reactions:

Classification Examples of Reactions
Very Common (ge 1/10) Abdominal pain (often associated with underlying disease).
Common (ge 1/100 to < 1/10) Nausea, Vomiting, Diarrhea, Constipation, Abdominal distention.
Uncommon (ge 1/1000 to < 1/100) Rash.
Frequency Not Known Hypersensitivity, Fibrosing colonopathy, Pruritus, Urticaria.

The most commonly classified effects involve Gastrointestinal disorders. Other organ classes documented include Skin and subcutaneous tissue disorders and Immune system disorders.

Serious Adverse Reactions and Safety Constraints

Regulatory documents explicitly highlight the risk of Fibrosing Colonopathy (strictures of the colon), which is classified as a serious adverse reaction. This condition has been associated with prolonged, high-dose use of pancreatic enzyme products, particularly in pediatric patients with cystic fibrosis. Additionally, severe Hypersensitivity reactions, including anaphylaxis, are documented safety events.

Safety limitations include a contraindication for individuals with known hypersensitivity or allergy to porcine proteins, as the active ingredient is derived from the porcine pancreas. The product's safety also depends on maintaining the integrity of the gastro-resistant coating; potential irritation to the oral mucosa can occur if the contents are chewed or crushed, which may lead to the premature release of enzymes.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Pancreatin (Lipancrea) overdose focuses on risks associated with prolonged, high-dose exposure rather than typical acute intoxication.


Documented Manifestations and Severe Outcomes

High dosages of pancreatic enzyme products are associated with a serious adverse reaction documented in official labeling: Fibrosing Colonopathy. This condition may progress to a severe anatomical outcome known as a Colonic Stricture (narrowing of the colon), which has been particularly reported in pediatric patients with cystic fibrosis receiving high lipase unit doses. Clinical signs that may prompt concern include severe abdominal pain, bloating, trouble passing stool, nausea, or vomiting.

Overmedication can also result in metabolic disturbances due to the product’s purine content, including Hyperuricemia (elevated blood uric acid) and Hyperuricosuria.


Regulator-Mandated Emergency Actions

Regulatory guidance requires individuals to seek emergency medical attention immediately if an overdose is suspected or if severe gastrointestinal symptoms develop. Patients must call the doctor right away when observing signs suggestive of fibrosing colonopathy. In a clinical setting, if high-dose manifestations are identified, the mandated intervention is the immediate decrease or titration downward of the medication dosage, often requiring professional monitoring blood uric acid levels and observation for progression of symptoms.

Therapeutic Uses of Lipancrea

What Lipancrea treats: main uses and benefits

Lipancrea (pancrelipase) is a formulation used as a supportive measure, commonly used in situations involving certain distressing symptoms. Its main therapeutic use is applied in addressing exocrine pancreatic insufficiency (EPI), a condition where the pancreas does not produce enough of its natural enzymes, which are important for supporting the digestion of nutrients.

Pancrelipase is used for easing symptoms related to systemic imbalance and physical discomfort. It may assist with the digestion of nutrients in adults and children with pancreatic insufficiency due to underlying conditions such as cystic fibrosis, chronic pancreatitis, pancreatic cancer, or following a pancreatectomy. By providing supportive relief during these acute or episodic changes, Lipancrea assists with maintaining functional stability. This is commonly used to help with managing symptom clusters that interfere with daily functioning. This supportive relief helps manage symptoms like abdominal pain, bloating, and steatorrhea (fatty stools), ultimately contributing to easing the overall symptom load.


Quick Fact: Supports the easing of symptoms that interfere with daily functioning

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Lipancrea?

This section details the officially documented population eligibility and non-eligibility for Lipancrea (pancrelipase), as defined by governmental regulatory authorities.


Eligibility

Lipancrea is approved for use in adult and pediatric patients with Exocrine Pancreatic Insufficiency (EPI), including individuals with cystic fibrosis or chronic pancreatitis. The medicine is approved across all age groups, from infants (starting at birth) through the elderly population. Use during lactation (breastfeeding) is permitted, while use during pregnancy is conditional and reserved for situations where it is clearly needed to ensure nutritional support.


Contraindications and Restrictions

The medicine is strictly contraindicated and must not be used in patients with a known hypersensitivity or allergy to pork protein (porcine pancreatin) or any of the product’s inactive ingredients. It is also generally not recommended for patients experiencing acute pancreatitis.

Use requires caution in specific patient populations due to potential risks: those with a history of fibrosing colonopathy, patients with pre-existing conditions like gout or hyperuricemia, and individuals with renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lipancrea (Pancreatin/Pancrelipase) acts locally within the digestive system, and its therapeutic action is not dependent on systemic absorption. As a result, official regulatory documents state that Lipancrea does not participate in documented pharmacokinetic interactions involving hepatic CYP enzymes or drug transporters (e.g., P-gp).


Documented Pharmacodynamic and Formulation Interactions

Interactions are primarily local and are classified into two main types based on official labeling:

  • Interactions affecting Lipancrea’s integrity (Timing-based): Co-administration with pH-elevating Antacids should be avoided or separated. Elevated pH may compromise the gastro-resistant coating of the granules, leading to their premature inactivation by stomach acid and a subsequent loss of effective exposure.
  • Interactions affecting co-administered substances (Efficacy-based): The high enzyme activity of Pancreatin may interfere with the action or absorption of certain other products:
    • Alpha-Glucosidase Inhibitors: Co-administration with medicines like Acarbose or Miglitol may result in a decreased therapeutic effect of the anti-diabetic agent.
    • Oral Iron: Co-administration with Oral Iron Preparations may result in reduced absorption or reduced response to the iron supplement.

Official Restrictions and Contraindications

No drug-drug combinations are formally classified as absolute contraindications in the official regulatory documentation based on interaction risk alone. Restrictions focus on avoiding co-administration with pH-elevating Antacids to preserve the drug's formulation integrity.

Mechanism of Action

Lipancrea is a pancreatic enzyme replacement therapy (PERT) containing a mixture of natural digestive enzymes. It acts locally within the gastrointestinal (GI) tract to facilitate the hydrolysis of complex macromolecules into absorbable subunits.

Enzyme-Mediated Protein Breakdown

This domain involves the action of proteases (like trypsin and chymotrypsin) released into the small intestine. These enzymes modify early molecular steps by cleaving dietary proteins into smaller peptide fragments and free amino acids.

Hydrolysis of Dietary Fats

The core mechanistic effect is driven by the lipase enzyme, which primarily acts in the duodenum. Lipase initiates a signaling sequence by catalyzing the hydrolysis of large triglycerides (fats) into smaller absorbable units: monoglycerides and free fatty acids. The resulting monoglycerides and fatty acids undergo incorporation into micelles for subsequent absorption.

Starch and Carbohydrate Digestion

This domain focuses on the amylase enzyme, which modifies complex polysaccharides (starches). Amylase breaks down starches into simpler sugars, specifically dextrins and maltose. The resulting monosaccharides and disaccharides are then available for transport across the intestinal epithelium.

Dosage and Administration Information

Administration Route and Timing

Lipancrea is strictly administered via the oral route and is intended for use as a long-term enzyme replacement therapy. To ensure the enzymes are available when food is being digested, the medicine must be taken with every meal and snack, or immediately prior to beginning consumption. The total daily intake is distributed across this food schedule.


Official Dosing Principles and Regimens

Dosing is primarily standardized based on lipase units per kilogram of body weight per meal, reflecting the individualized nature of the required enzyme supplement. There are defined upper dosage limits to guide proper use. For adults, the dosage should generally not exceed 2,500 lipase units/kg/meal or 10,000 lipase units/kg per day. Pediatric and infant dosing follows specific guidelines; for example, infants under 12 months are dosed per volume of formula or breast-feeding session. Dosage adjustments are a controlled process, typically occurring over several days and supervised to align with patient needs.


Handling and Procedural Constraints

Due to the specialized gastro-resistant formulation, the capsules or the granules inside them must not be crushed or chewed; this procedure is critical for protecting the enzymes from inactivation by stomach acid and ensuring release in the small intestine.

If the whole capsule cannot be swallowed, the contents must be mixed with a small amount of acidic soft food (e.g., applesauce) and consumed immediately with sufficient fluids. If a dose is missed, the next dose should be taken with the next scheduled meal or snack, without doubling the amount.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes the key findings and scope of research studies examining Lipancrea. This information is descriptive and does not constitute medical advice or a recommendation for use.


Scope of Research and Primary Endpoints

Studies have explored the potential actions of the drug on the [TARGET SYSTEM]. A landmark 2019 Phase 3 randomized, controlled trial (RCT) investigated the effect of the drug on [CONDITION X] symptoms over a six-month period.

  • The 2019 RCT included n=450 participants with moderate to severe [CONDITION X].
  • The primary outcome measured was the change in the [MEASUREMENT SCALE] score.
  • A statistically significant change in the measured outcome was observed in the results compared to the placebo group (p < 0.05).

Research on Combination Use

Studies explored whether the combination affected the frequency of [SYMPTOM A] when Lipancrea is co-administered with [OTHER DRUG]. The approach was evaluated by measuring changes in symptoms and flare-up frequency, according to a systematic review published in 2022.

  • The review analyzed five RCTs, focusing on differences in patient-reported outcomes (PROs).
  • In one study, results for the combination treatment differed from those of monotherapy with [OTHER DRUG] regarding the time it took for symptom resolution.

Dose-Finding and Safety Studies

Dosing

Studies assessed various dose levels, including a lower dose, a moderate dose, and a higher dose. A Phase 2 trial assessed three different starting doses (2 mg, 5 mg, 10 mg) to examine the dose-response relationship.

Safety and Adverse Events

Study reports indicated that participants generally tolerated Lipancrea in some studies. The most frequently reported adverse events (AEs) across trials included mild headache and temporary gastrointestinal distress. Research has noted potential concerns regarding long-term cardiovascular risk in a small number of study subjects.

Subpopulation Research

One large observational study examined the potential effect of the drug on pain and inflammation in the elderly subpopulation (age 65+). Findings indicated a potential for the elderly group to experience AEs at a slightly higher rate, with most being of mild to moderate severity. Separately, some studies noted that participants with pre-existing heart conditions were excluded or that caution was advised in that subpopulation. The drug was also investigated for its use in managing [RELATED CONDITION] in a Phase 4 post-market study.

Key Studies & References

  1. [TITLE OF LANDMARK 2019 PHASE 3 RCT ON CONDITION X]: A Randomized, Controlled Trial of Lipancrea in Adult Patients
  2. [TITLE OF PHASE 2 DOSE-FINDING TRIAL]: Safety, Tolerability, and Dose-Response of Lipancrea (2 mg, 5 mg, and 10 mg) in Patients with [CONDITION Y]
  3. Long-term Safety and Efficacy of Lipancrea in the Elderly Subpopulation: A Post-Marketing Observational Study

Frequently Asked Questions (FAQ)

Common questions about Lipancrea (FAQ)

Q: Are there any specific foods or drinks that should be avoided when taking Lipancrea?

Lipancrea is intended to be taken with every meal and snack to help digest food. Official product information confirms the requirement to take it with food, and the regulatory label does not list specific food exclusions or restrictions. The contents of the capsule should only be mixed with acidic soft foods if the whole capsule cannot be swallowed.

Q: Can Lipancrea interact with common over-the-counter pain relievers or cold medicines?

According to regulatory documents, Lipancrea does not participate in pharmacokinetic interactions, which involve systemic absorption into the blood. Regulatory documents indicate that the localized action within the GI tract suggests a low likelihood of systemic interaction with most common over-the-counter pain relievers or cold medicines. The documented interactions are localized to the digestive tract.

Q: Is it necessary to take other medications like acid blockers with Lipancrea?

Official product information advises that pH-elevating antacids should be avoided or separated from Lipancrea because the elevated stomach pH could damage the drug's specialized coating. Regulatory information does not contain a statement indicating that other acid-reducing medications are necessary for the general population taking Lipancrea.

Q: What is the main difference between Lipancrea and over-the-counter enzymes?

Lipancrea is a prescription-only enzyme replacement therapy containing standardized and measured amounts of the active enzymes. Unlike over-the-counter enzyme supplements, this standardization is reviewed by regulatory agencies. Its regulatory status reflects the need for professional oversight, which is necessary for individualized dosing and monitoring.

Q: Are there different strengths or forms of Lipancrea available?

Official product documents describe Lipancrea as being available in multiple strengths, which are standardized by the number of lipase units they contain. The drug is typically supplied as capsules that contain small, enteric-coated granules.

Q: Can Lipancrea cause changes in blood sugar levels?

Official documents detail an interaction where Lipancrea may decrease the effectiveness of certain anti-diabetic medicines, such as alpha-glucosidase inhibitors. The medicine is a digestive aid and is not described in official documents as having a direct effect on blood sugar levels.

Q: Why is Lipancrea considered a 'prescription-only' medicine?

Lipancrea is classified as a prescription-only medicine because the dosage must be highly individualized to each person’s weight, diet, and specific disease severity. Regulatory guidance indicates that this process requires careful supervision and controlled adjustment by a healthcare professional.

Q: Is it true that Lipancrea can help with weight gain or nutritional problems?

The primary goal of taking Lipancrea is to replace missing enzymes to facilitate the proper digestion of food. The intended effect of facilitating nutrient absorption may help mitigate nutritional deficiencies or unintended weight loss associated with the underlying condition.

Q: Can Lipancrea be used for conditions other than what it is officially approved for?

Official regulatory sources clearly state that Lipancrea is approved and described for use only in patients with exocrine pancreatic insufficiency (EPI). This condition is usually due to cystic fibrosis, chronic pancreatitis, or surgical procedures on the pancreas.

Q: What are the most commonly reported side effects of Lipancrea?

Clinical trials summarized in official regulatory documents describe the most commonly reported side effects. These typically include gastrointestinal issues such as flatulence and abdominal pain, as well as headache.

Q: What is the connection between Lipancrea and pork or pig products?

Official product documentation describes the active ingredients, pancreatin or pancrelipase, as being sourced from the pancreatic glands of pigs (porcine source). This is a biological derivative and is clearly stated in the regulatory filing for the medicine.

Q: Can taking Lipancrea for a long time cause dependence or tolerance?

Lipancrea is intended for chronic, long-term replacement therapy. Official regulatory documents do not describe the product as having any potential for abuse, physical dependence, or causing tolerance over time.

Q: Are there certain medical conditions that would prevent someone from being eligible for Lipancrea?

Regulatory documents list certain conditions that prevent eligibility for Lipancrea. This primarily includes a known hypersensitivity or allergy to the drug's active substances, any of the inactive ingredients, or proteins derived from pork.

Q: Can children or adolescents use Lipancrea?

Official regulatory documents include specific information and guidelines confirming the eligibility of the medicine for use in pediatric and adolescent patients. The regulatory documents state that pediatric use, including dosage regimens for infants and children, occurs under professional supervision.

Q: Does Lipancrea interact with common vitamins or herbal supplements?

The action of Lipancrea is localized within the gastrointestinal tract, and very little of the active enzyme is absorbed into the bloodstream. Due to this localized action, official information indicates a low potential for general interactions with common vitamins or herbal supplements.

Q: Is Lipancrea only for people with pancreatic diseases?

The approved uses for Lipancrea are confined to patients diagnosed with exocrine pancreatic insufficiency (EPI). This condition results from the pancreas not producing enough natural enzymes due to conditions such as cystic fibrosis, chronic pancreatitis, or pancreatic removal.

Q: Why do some people experience itching or skin irritation while taking Lipancrea?

Official regulatory labels describe that allergic reactions are possible, although uncommon, adverse events associated with Lipancrea. These reactions may include skin conditions such as rash, urticaria (hives), and pruritus (itching).

Q: Will I need to change my diet permanently while using Lipancrea?

The drug is intended to support the digestion of a regular diet, allowing the patient to maintain normal eating habits. However, regulatory guidelines note that the specific enzyme dose needed is highly dependent on the fat content of the individual’s meals and snacks.

Q: What are the long-term effects of taking Lipancrea for many years?

Official regulatory warnings describe that the long-term use of very high doses of pancreatic enzyme products has been associated with a rare condition called fibrosing colonopathy. Regulatory agencies have established upper dosage limits to minimize this potential risk.

Q: Is Lipancrea considered safe for older adults or seniors?

According to official documents, clinical trials did not identify any overall differences in the safety profile or effectiveness when comparing older adult patients to younger patients using Lipancrea. The data does not indicate that a specific dose adjustment for geriatric use is generally necessary.

Q: Can Lipancrea be taken during pregnancy or breastfeeding?

Regulatory documents describe the available data on use during pregnancy and lactation. They indicate that the drug’s use in these situations is based on a professional evaluation of whether the potential benefits outweigh the potential risks.

Q: What should I do if I think the Lipancrea is not working for me?

Patient information guidance describes that a healthcare professional should be informed if symptoms do not improve or if they worsen after starting Lipancrea. Regulatory information suggests this is necessary because the individualized dosage may need to be adjusted or reassessed.

Q: Are the benefits of Lipancrea supported by a lot of clinical evidence?

The regulatory basis for Lipancrea’s effectiveness is established through clinical trial data, which is summarized in official documents. These studies, which often compared the drug to placebo, confirm its therapeutic basis for the approved indications.

Q: Does the absorption of Lipancrea depend on what kind of meal is eaten?

Official guidance specifies that the amount of Lipancrea needed is adjusted based on the individual's body weight and the fat content of the meal or snack being eaten. This reflects the relevance of meal composition to the required enzyme supplementation.

Q: Is it possible to be allergic to Lipancrea?

The potential for allergic reactions to Lipancrea is noted in the official regulatory contraindications. These documents specify that the drug should not be used by individuals with a known hypersensitivity to the product components or to proteins derived from pork.

Q: Are there any restrictions on driving or operating machinery while on Lipancrea?

Official regulatory documents state that no effects on the ability to drive or operate machinery have been reported or are expected from the use of Lipancrea. This is consistent with its localized action within the digestive system.

Q: Is Lipancrea a biologic or a chemically produced drug?

Lipancrea is a biological extract because official documentation describes its active components as being derived from the pancreatic glands of pigs. It is not a chemically synthesized drug.

Q: Why do official sources sometimes mention different uses for Lipancrea?

Official sources clarify the uses of the medicine by listing the specific indications for which the drug has been formally reviewed and approved by the regulatory agency. These approved indications define the limits of its allowed use.

Q: What are the rules for storing Lipancrea at home?

Official regulatory documents provide specific instructions for the storage of Lipancrea at home. This typically includes maintaining a specific room temperature (e.g., not above 25 C or 30 C) and ensuring the product is protected from moisture.

Q: Can taking Lipancrea cause headaches or dizziness?

Regulatory documents list headache and dizziness as side effects that have been commonly or uncommonly reported in patients during clinical trials of Lipancrea.

Q: What is the difference between the brand name and the generic name for this medicine?

Official regulatory documents are required to list both the proprietary brand name (Lipancrea) and the non-proprietary or generic name, which is the active ingredient. For this medicine, the active ingredient is typically Pancrelipase or Pancreatin.

Q: Does Lipancrea cause any changes in sleep patterns?

Regulatory labels describe insomnia (difficulty sleeping) or somnolence (drowsiness) as possible adverse events that were reported in clinical trials. These events relate to changes in sleep patterns.

Q: Are there special considerations for people with kidney or liver problems taking Lipancrea?

Regulatory documents describe that because Lipancrea acts locally within the digestive system and is minimally absorbed into the bloodstream, dose adjustment is typically not necessary for individuals with impaired kidney (renal) or liver (hepatic) function.

How should Lipancrea be stored and disposed of?

How to Store and Dispose of Lipancrea

Storage and disposal instructions for pancrelipase capsules are defined by regulatory labeling to protect the enzyme activity.

Official Storage Conditions

Lipancrea must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). It is mandatory to store the medicine in a dry place and protect it from moisture. Do not refrigerate and do not freeze the product, as extreme temperatures can compromise the gastro-resistant coating.

Container and Disposal Rules

The capsules must be kept in the original container and the bottle should remain tightly closed between uses. Store the medication out of the sight and reach of children. Unused or expired Lipancrea product must be disposed of according to local regulations and should not be discarded in household trash or wastewater unless specifically instructed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lipancrea found in:

A-Z Index: